|
Apr 11
|
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?
|
|
Apr 11
|
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
|
|
Apr 11
|
Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says
|
|
Apr 11
|
3 Value Stocks in the Doghouse
|
|
Apr 10
|
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
|
|
Apr 10
|
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
|
|
Apr 9
|
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today
|
|
Apr 9
|
Sector Update: Health Care Stocks Gain Late Afternoon
|
|
Apr 9
|
Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in
|
|
Apr 9
|
Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy
|
|
Apr 9
|
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
|
|
Apr 9
|
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
|
|
Apr 9
|
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients
|
|
Apr 9
|
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
|
|
Apr 8
|
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
|
|
Apr 8
|
Goldman turns cautious on major pharma names, sees select upside at Eli Lilly
|
|
Feb 17
|
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now
|
|
Feb 16
|
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
|
|
Feb 14
|
BioArctic AB (BRCTF) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Profitability ...
|
|
Feb 13
|
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
|